Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| REN-M5222 | Mouse | Mouse RENIN Protein, His Tag |  |
|
|
| REN-H5221 | Human | Human RENIN Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Hypertension; Essential Hypertension | Details | |
| Aliskiren Hemifumarate | SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B | Approved | Novartis Pharma Ag | Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Myocardial Ischemia; Heart Failure; Myocardial Infarction; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Diabetic Nephropathies; Essential Hypertension; Overweight; Diabetes Mellitus; Kidney Failure, Chronic | Details |
| Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SPH-3127 | I001-A; I001-B; [14C]SPH3127; SPH-3127; MT-2765; MT2765; I-001 | Phase 3 Clinical | Mitsubishi Tanabe Pharma, Shanghai Pharmaceuticals Holding Co Ltd | Kidney Diseases; Hypertension; Psoriasis; Essential Hypertension; Diabetic Nephropathies; Colitis, Ulcerative | Details |
| MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
| SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
| Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Renal Insufficiency; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency | Details |
This web search service is supported by Google Inc.
A-Z
